We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER Features Valsartan in Report on Drug Safety Priorities for 2018
CDER Features Valsartan in Report on Drug Safety Priorities for 2018
CDER released its latest annual report on drug safety priorities on Tuesday, detailing how it approached drug safety in 2018 — including how it handled the valsartan impurity crisis.